SCHEMBL2402008

SCHEMBL2402008

CC(C)N1CCN(C(=O)C2CCC(NS(=O)(=O)c3cc(F)c(F)c(F)c3)CC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.42
TDP1 Q9NUW8 1/20 0.42
MEN1 O00255 3/20 0.41
MMP2 P08253 1/20 0.40
MMP13 P45452 1/20 0.40
HRH3 Q9Y5N1 3/20 0.40
ALDH1A1 P00352 2/20 0.39
CNR1 P21554 1/20 0.38
DPP4 P27487 1/20 0.37
DPP7 Q9UHL4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
BDKRB1 P46663 1/20 0.37
SFRP1 Q8N474 1/20 0.36
RORC P51449 1/20 0.36
DRD2 P14416 1/20 0.36
ADRA1D P25100 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2402005 1.00 KMT2A (0.42) KMT2ATDP1MEN1MMP2MMP13
SCHEMBL2404245 1.00 KMT2A (0.42) KMT2ATDP1MEN1MMP2MMP13
SCHEMBL2404226 0.89 KMT2A (0.58) KMT2ATDP1MEN1MMP2MMP13
SCHEMBL2404229 0.89 KMT2A (0.58) KMT2ATDP1MEN1MMP2MMP13
SCHEMBL2404388 0.89 KMT2A (0.58) KMT2ATDP1MEN1MMP2MMP13
SCHEMBL2401696 0.86 L3MBTL1 (0.50) KMT2AMEN1MMP2MMP13HRH3
SCHEMBL2401700 0.86 L3MBTL1 (0.50) KMT2AMEN1MMP2MMP13HRH3
SCHEMBL2400473 0.85 CNR1 (0.47) KMT2ATDP1MEN1MMP2MMP13
SCHEMBL2400476 0.85 CNR1 (0.47) KMT2ATDP1MEN1MMP2MMP13
SCHEMBL2404113 0.85 CNR1 (0.47) KMT2ATDP1MEN1MMP2MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017773-B2 Cyclohexyl sulfonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2011-09-13 US disclosed
EP-1979322-B1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY HOFFMANN LA ROCHE (CH) 2010-09-01 EP disclosed
US-20100120791-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES NETTEKOVEN MATTHIAS 2010-05-13 US disclosed
EP-1979322-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2008-10-15 EP disclosed
WO-2007082840-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2007-07-26 WO disclosed
US-20070173511-A1 Cyclohexyl sulfonamide derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120791-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HRH3, HRH4, HRH1 KMT2A 338/4885TDP1 4241/4885MEN1 3462/4885
US-20070173511-A1 Cyclohexyl sulfonamide derivatives HRH3, HRH4, HRH1 KMT2A 338/4885TDP1 4241/4885MEN1 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.